Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
We recently reiterated our Neutral recommendation on Broadcom Corporation (BRCM - Analyst Report).
Fueled by the broadband communications explosion, Broadcomhas enjoyed robust growth since its inception. The company is focused on the most innovative technologies related to connectivity, bandwidth and content. The continued expansion of pay-TV and Internet access services internationally, especially in China and India, provide significant opportunity for growth.
Broadcom is well positioned in the fast-growing wired and wireless communications markets, with cutting-edge solutions for a growing number of connected users that demand more content and bandwidth. In particular, strong demand for smartphones and tablets, particularly from customers like Samsung and Apple, is boosting Broadcom's growth.
The company recently launched the industry’s first SOC devices with the potential of 5G WiFi. These chips enable fastest and most reliable Gigabit connectivity for home and small/medium business (SMB) networks. These chips will complement the company’s full line of5G WiFi 802.11ac solutions. With the ever-growing demand for wireless connectivity ubiquitously, there is increasing reliance on wireless networks, which in turn, stresses the legacy 802.11a/b/g/n networks. The new 5G WiFi enables mobile device users to stream digital content between devices faster, and simultaneously connect more wireless devices to home and enterprise networks, while conserving battery power.
Earlier, earnings estimates jumped significantly after the company reported better-than-expected results for the first quarter of 2012.
Broadcom’s product leadership, solid financial performance and strong cash flow generation continue to be positives. However, we remain concerned about the pressure on margins due to the accelerated new product ramps, continuous acquisitions and business concentration. We await a better entry point, and therefore continue to maintain our Neutral recommendation on the stock.
Our Neutral recommendation is supported by a Zacks #3 Rank, which translates into a short-term rating of Hold.
Get the full Analyst Report on BRCM - FREE